RNA interference approaches for treatment of HIV-1 infection by unknown
Bobbin et al. Genome Medicine  (2015) 7:50 
DOI 10.1186/s13073-015-0174-yREVIEW Open AccessRNA interference approaches for treatment of
HIV-1 infection
Maggie L Bobbin1, John C Burnett1,2 and John J Rossi1,2*Abstract
HIV/AIDS is a chronic and debilitating disease that
cannot be cured with current antiretroviral drugs. While
combinatorial antiretroviral therapy (cART) can potently
suppress HIV-1 replication and delay the onset of AIDS,
viral mutagenesis often leads to viral escape from
multiple drugs. In addition to the pharmacological
agents that comprise cART drug cocktails, new biological
therapeutics are reaching the clinic. These include
gene-based therapies that utilize RNA interference
(RNAi) to silence the expression of viral or host
mRNA targets that are required for HIV-1 infection
and/or replication. RNAi allows sequence-specific
design to compensate for viral mutants and natural
variants, thereby drastically expanding the number
of therapeutic targets beyond the capabilities of cART.
Recent advances in clinical and preclinical studies have
demonstrated the promise of RNAi therapeutics,
reinforcing the concept that RNAi-based agents might
offer a safe, effective, and more durable approach for
the treatment of HIV/AIDS. Nevertheless, there are
challenges that must be overcome in order for
RNAi therapeutics to reach their clinical potential.
These include the refinement of strategies for delivery
and to reduce the risk of mutational escape. In this
review, we provide an overview of RNAi-based therapies
for HIV-1, examine a variety of combinatorial RNAi
strategies, and discuss approaches for ex vivo delivery
and in vivo delivery.and availability of antiretroviral drugs and efforts in HIV/* Correspondence: jrossi@coh.org
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The genome of the human immunodeficiency virus-1 (HIV-1)
is composed of nine viral genes (gag, pol, vif, vpr, tat, rev,
vpu, env, and nef ) that are required for all processes in the
viral replicative cycle, including viral assembly, viral entry
and receptor binding, membrane fusion, reverse tran-
scription, integration, and proteolytic protein process-
ing (Fig. 1). HIV-1 preferentially infects human CD4+
T-lymphocytes, eventually leading to a depletion of CD4+
cells and the clinical progression to acquired immunodefi-
ciency syndrome (AIDS). Since the discovery of the anti-
retroviral activity of azidothymidine (AZT) in 1985 [1], a
variety of antiretroviral drugs have been developed that
target multiple steps in the viral replication cycle (Table 1).
Typically, a cocktail of three antiretroviral drugs is used
as a combinatorial antiretroviral therapy (cART) that
can effectively suppress viral replication, reduce rates of
transmission, and improve patients’ life expectancy by
prolonging the onset of AIDS [2]. Nevertheless, cART
does not fully restore health, as patients on cART still ex-
perience chronic inflammation and increased rates of
non-AIDS morbidity and mortality [3]. Moreover, current
cART regimens are unable to cure HIV-1 patients, as
these drugs cannot eradicate latent viral reservoirs and
may also fall short in completely suppressing viral replica-
tion despite drug intensification [4–7]. Thus, nearly all
HIV-infected individuals on cART will need to maintain
their medications for the entirety of their lives, resulting
in considerable expense, development of resistance, and
toxic side effects. Owing to improvements in the efficacy
AIDS prevention, recent years have seen a decrease in the
incidence of HIV-1 infection. Nevertheless, there are still
35.3 million people living with HIV-1, with 2.3 million
new cases and 1.6 million deaths in 2012 [8]. Because of
the limitations and adverse effects associated with current
cART regimens, it is necessary to develop alternative
therapeutic strategies that are safer, more efficacious,
and more resistant to viral escape. Such emerging thera-
peutic strategies include gene-based and nucleic-acid-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Fig. 1 The HIV-1 genome and strategies for antiviral targeting. a Structure of the HIV-1 genome. The genome contains nine genes and two long
terminal repeats (LTRs) that can be targeted by RNA interference (RNAi). Certain genomic regions are more conserved than others, making them
better targets. In addition, many of the genes are alternatively spliced, requiring careful target design. b HIV-1 targeting. Several steps of the HIV-1
viral replication cycle can be targeted by RNAi. Current drug targets are in parentheses. (1) The first step is receptor binding and membrane fusion
by the HIV envelope glycoproteins gp120 and gp41 to host receptors CD4 and either CCR5 or CXCR4. This step can be inhibited by knocking
down the HIV-1 co-receptors, CCR5 or CXCR4. (2) Next, the viral genome must be reverse transcribed by the viral reverse transcriptase (RT) and
(3) integrated into the cellular genome which is mediated by the viral integrase protein and host factors LEDGF, Importin, and Chaperonin.
After integration, (4) the virus is transcribed, which is mediated by viral (TAR and tat) and host (pTEFb, tat-SF1, SPT5, cyclin T1) factors,
(5) exported to the cytoplasm (dependent on DDX3 and Rev) and then translated and (6) subjected to post-translational processing by
the viral protease. (7) Finally, the proteins are processed and (8) packaged into new viral particles
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and RNA interference (RNAi).
Like cART, gene-therapy strategies against HIV-1 are
often designed to target multiple viral mechanisms, which
reduces the possibility of viral-escape-induced drug resist-
ance and improves therapeutic efficacy. This is particularly
true for RNAi therapeutics, as small interfering RNAs(siRNAs) and short hairpin RNAs (shRNAs) can be de-
signed to target conserved 21-nucleotide sequences within
the 9.2-kb HIV-1 genomic RNA, thereby expanding the
possible targets far beyond those of current drugs. More-
over, multiplexing siRNAs or shRNAs as a single therapy
can increase the overall potency and reduce the dosage of
each component required to minimize off-target toxicity.
Table 1 Current therapies, clinical trials, and strategies to combat HIV
Therapeutic approach Company/institute Component(s) Target(s) Delivery Progress NCT identifier Reference(s)
Combinatorial anti-retroviral
therapy (cART)
Gilead, Merck, GSK, Pfizer,
Tibotec, Abbott, Bristol-Meyers
Squibb, Hoffman-La Roche
1. CCR5 antagonist 1. Receptor binding In vivo drug administration Current method
to treat HIV
[159]
2. Fusion inhibitors 2. Membrane fusion
3. Nucleoside analogs or
RT inhibitors
3. Reverse transcription
4. Strand transfer inhibitor 4. Integration
5. Protease inhibitors 5. Protein processing
Peptide or protein vaccines VaxGen, Merck, NIH/NIAID Gp120 Viral envelope In vivo injection Phase I/II/III NCT00001031 [160–162]
Gp41/160 NCT00002402
Gag/pol/nef Viral proteins NCT00223080
NCT01435135
NCT00002441
Inhibitory peptide University Medical Center
Hamburg-Eppendorf
C46 anti-viral peptide Viral fusion to cell
membrane
Ex vivo retroviral modified
CD4+ cells
Phase I [163]
Drug shRNA peptide Calimmune/Caltech/UCLA 1. Bisulfide 1. Transplant conditioning Ex vivo lentiviral modified
CD34+ and CD4+ cells
Phase I/II NCT01734850 [139]
2. CCR5 shRNA 2. Host co-receptor
3. C46 peptide 3. Viral envelope
shRNA ribozyme RNA
decoy
Benitec/City of Hope 1. tat/rev shRNA 1. Viral mRNA Ex vivo lentiviral modified
CD34+ cells
Phase I NCT00569985 [38, 39]
2. CCR5 ribozyme 2. Host co-receptor
3. TAR decoy 3. Viral Tat protein
Zinc finger nuclease Sangamo Biosciences 1. CCR5 zinc finger nuclease CCR5 DNA Ex vivo AAV modified
autologous CD4+ T cells




Ribozyme Janssen-Cilag Pty Ltd, UCLA tat-vpr anti-HIV ribozyme Tat-vpr mRNA Ex vivo retroviral modified
autologous CD34+ HPC
Phase I/II NCT00074997 [40, 41]
NCT01177059
Ribozyme UCSD CCR5 ribozyme CCR5 mRNA Ex vivo retroviral modified
autologous CD4+ T cells
Phase I FDA BB-IND 6405 [42]
Ribozyme Johnson & Johnson,
St Vincent’s Hospital
Tat anti-HIV ribozyme Translation initiation
mRNA of Tat
Ex vivo retroviral modified
syngeneic CD4+ T cells
Phase I NCT00074997 [43]
Ribozyme Ribozyme, City of Hope Tat anti-HIV ribozyme Tat-rev mRNA Ex vivo retroviral modified
CD34+ HPC













Table 1 Current therapies, clinical trials, and strategies to combat HIV (Continued)
Antisense VIRxSYS Corporation 937 base antisense gene Env mRNA Ex vivo lentiviral (LTR HIV)
modified CD4+ cells
Phase I/II NCT00131560 [165]
Antisense Enzo Biochem U1/HIV anti-sense RNA
(61–68 bases)
TAR, tat/rev Ex vivo retroviral modified
CD34+ HPC
Phase I/II NCT00003942 [166]
NCT00001535
RNA decoy Children’s Hospital
Los Angeles
Rev response element decoy Rev protein Ex vivo retroviral modified
CD34+ HPC
Phase 0- pilot [167]
Abbreviations: AAV, adeno-associated virus; HPC, human progenitor cells; LTR, long terminal repeat; NCT, National Clinical Trial; NIH/NIAID, National Institutes of Health/National Institute of Allergy and Infectious
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technologies for the treatment and eradication of HIV-1.
Many new therapies are currently in development with
the hope of preventing drug resistance, toxicity, and la-
tent infection. Owing to their design flexibility and target
specificity, we pay particular attention to RNAi-based
therapies that target viral or host targets, including some
that have reached human clinical testing. Delivery of the
RNAi agents to HIV-infected or HIV-susceptible cells
remains a challenging problem that is currently being
addressed by ex vivo delivery, targeted in vivo delivery,
and non-targeted in vivo delivery strategies.
HIV-1 infection and therapeutic targets
HIV-1 gains entry into CD4-expressing T-lymphocytes,
macrophages, and monocytes by fusion of the viral enve-
lope with the host cell membrane (reviewed in [9]). The
HIV-1 envelope is characterized by trimeric spikes, and
each spike contains three glycoprotein 120 (gp120) surface
subunits and three gp41 trans-membrane subunits. The
process of viral binding and entry into the cell generally
requires the CD4 receptor and either the CCR5 or the
CXCR4 co-receptor. Upon receptor-mediated binding and
internalization, the viral RNA genome is converted to
double-stranded DNA, using reverse transcriptase that is
provided by the virus. The viral genomic DNA is then
imported into the nucleus and integrated into the host
genome, where it is transcribed into the full-length 9.2-kb
mRNA transcript. This transcript can undergo double spli-
cing into 1.8-kb mRNAs encoding Tat, Rev, and Nef pro-
teins. Tat and Rev travel to the nucleus where Tat activates
transcription and Rev mediates the export of mRNAs in
the late phase. Singly-spliced 4.0-kb transcripts encod-
ing Env, Vpu, Vpr, and Vif proteins [10] and unspliced
9.2-kb mRNA transcripts encoding Gag and Gag-Pol are
exported from the nucleus in a Rev-dependent manner.
These unspliced mRNAs also function as the genomic
RNA for progeny virus. Several Gag molecules bind to the
viral genome and are trafficked to lipid rafts on the plasma
membrane of the host cell [11, 12]. The viral genome is
assembled as a dimer with viral proteins and exits the cell
via budding. Final maturation occurs once the viral parti-
cles are released from the host cell. These steps provide
many opportunities for therapeutic intervention.
Owing to the limitations of current cART approaches,
alternative gene- and nucleic-acid-based therapies have
been proposed to control HIV-1 infection, including gene
editing, ribozymes, and utilization of RNA decoys. In
addition, gene- and nucleic-acid-based agents have been
developed as HIV-1 prophylactics, including RNA apta-
mers and siRNAs that are used as microbicides and viral
genes used as vaccines (Table 1).
Gene editing, which requires a sequence-specific nucle-
ase that modifies a target gene, is a particularly attractiveapproach that aims to develop cells that are permanently
resistant to HIV-1 infection or to eliminate the HIV-1 pro-
virus from infected cells [13]. HIV-resistant cells can be
established by genomic editing of the CCR5 or CXCR4
co-receptors using zinc finger nucleases (ZFNs) [14–21],
transcription activator-like effector nucleases (TALENs)
[22], designer endonucleases [23], peptide nucleic acids
(PNAs) [24], or CRISPR/Cas9 [22, 25, 26]. Alterna-
tively, the integrated HIV-1 genome in infected cells can
be targeted and destroyed using CRISPR/Cas9 [27, 28],
homing endonucleases [29], and HIV-1 long terminal
repeat (LTR)-specific recombinases [30–32]. Catalytic
RNAs, known as ribozymes, can complete a similar task,
but the effects are not permanent because their target
molecule is mRNA [33]. RNA aptamers and decoys can
bind viral proteins to act as steric or competitive inhibi-
tors [34–36]. By combining an anti-HIV-1 microRNA
(miRNA) with a TAR decoy (TARmiR), a dual-functioning
RNA molecule can suppress HIV-1 expression by RNAi
and also bind to the HIV-1 transactivating protein Tat, re-
ducing the numbers of Tat molecules that can bind to its
cognate target TAR to transactivate viral transcription
[37]. Several of these technologies have reached clinical
testing as single or combinatorial HIV-1 therapies [2], in-
cluding CCR5 ZFN [20], CCR5 ribozymes [38, 39], HIV-1
ribozymes [40–43], and TAR decoys [38, 39].
Endogenous RNA silencing pathway
RNAi is a natural cellular mechanism first identified by
Craig Mello and Andrew Fire in 1998, which involves
the pairing of a short miRNA sequence to an endogenous
mRNA target [44]. Endogenous miRNAs regulate many
cellular mechanisms and are processed in a very specific
manner. First, double-stranded miRNAs are loaded into
the RNA-induced silencing complex (RISC), where the
non-targeting (passenger) strand is removed. The RISC
complex then finds the complementary mRNA sequence
for the guide strand of the miRNA. The binding of the
miRNA to the mRNA target results in gene silencing
through degradation of the mRNA (Fig. 2). While the ca-
nonical RNAi pathway occurs in the cytoplasm, RNAi can
also function in the nucleus to induce gene-specific tran-
scriptional gene silencing or transcriptional gene activa-
tion by directing epigenetic changes in gene promoters
[45–47]. Teasing out these mechanisms has resulted in a
better understanding of how mammalian cells use this
system to regulate endogenous gene expression.
While the role of the RNAi system in mammalian cells is
well documented (reviewed in [48]), the role of mamma-
lian RNAi in response to viral infections is still the subject
of much debate [49]. It is well established that viral RNAs
trigger innate interferon (IFN) responses in mammalian
cells as a first line of defense. While viral small RNAs
(vsRNAs) have been detected in infected mammalian cells
Fig. 2 RNA silencing mechanism. For therapeutic RNAi applications, a lentiviral vector or plasmid is transcribed by RNA pol III into shRNA. This
shRNA is then exported from the nucleus to the cytoplasm by Exportin 5. After export, shRNA or miRNA are processed by Dicer and loaded into
RISC. For exogenously delivered siRNA or Dicer substrate RNA (dsiRNA), the processed siRNA is loaded directly into RISC. The passenger strand is
removed from the guide strand and RISC guides the remaining strand to its complementary mRNA target. RISC then cleaves the mRNA for
degradation. Abbreviations: pol III, RNA polymerase III; pol II, RNA polymerase II; RISC, RNA-induced silencing complex; shRNA, short hairpin RNA;
siRNA, short interfering RNA
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function via an antiviral RNAi pathway. One reason for
this uncertainty is that many viruses encode viral suppres-
sors of RNAi (VSRs), which are viral proteins that inhibit
the host RNAi pathway [51, 52]. Two important studies
from 2013, which examined conditions that are unfavor-
able for VSRs, reported that vsRNAs act via an RNAi
pathway [53, 54]. Encephalomyocarditis virus infection of
undifferentiated mouse embryonic stem cells, which have
low or no innate IFN response, resulted in the accumula-
tion of virus-derived siRNAs (vsiRNAs) that associated
with Argonaute-2 (Ago2) [53]. vsiRNAs were not, how-
ever, observed in differentiated cells, which have high in-
nate IFN activity. Thus, antiviral RNAi appears to be most
prevalent in conditions that are unfavorable for innate
IFN viral clearance. Similarly, infection by a Nodamura
virus strain that contained a mutant VSR protein wasattenuated because host cells produced vsRNAs in re-
sponse to infection with these mutant viruses [54]. Despite
these compelling reports, seemingly contradictory obser-
vations have recently been reported that indicate that viral
RNAi does not occur in Dicer-knockout cells or in cells
with disabled IFN function [55, 56]. Thus, the potential
role of antiviral RNAi in mammalians remains controver-
sial and appears to be highly dependent on the host cells
and the particular virus.
The RNA silencing pathway provides a tool for gene
therapy by the delivery of artificial RNAi in the form of a
small RNA duplex, such as a miRNA, siRNA, Dicer sub-
strate RNA (DsiRNA), or shRNA [57]. Although siRNA,
DsiRNA, and shRNA all function through the same RNAi
pathway, shRNA requires additional processing in the nu-
cleus (Fig. 2). shRNAs differ from siRNAs because they
comprise a single strand of RNA with two complementary
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scribed from viral vectors or plasmid DNA in the nucleus.
Following transcription, the shRNA is exported to the
cytoplasm, where it is processed in the same manner as
siRNA by Dicer in complex with TRBP, a member of the
RISC. Alternatively, Dicer-independent Ago2-shRNAs are
shRNAs that have a short stem length and are incorpo-
rated into RISC without Dicer processing [58]. After in-
corporation into RISC, the processed siRNA is loaded
onto an mRNA target to induce either mRNA cleavage by
Ago2 or translational repression and subsequent mRNA
degradation.
Toxicity of RNAi can occur through improper target
recognition resulting from suboptimal annealing of the
antisense guide strand to the target strand, improper se-
lection of an unintended passenger strand by the RISC
complex, or overloading of the silencing machinery.
Biasing the strand-selection of the guide strand, rather
than of the passenger strand, can enhance potency while
also reducing off-target effects of the passenger strand.
Strand selection can be biased by designing asymmetric
siRNAs with less stable thermodynamic stability at the
5′ end of the guide strand [59, 60], by chemical modifica-
tions at one or both ends of the siRNA [61, 62], or by the
design of structurally asymmetric shRNAs or siRNAs that
have a single 2-nucleotide 3′-overhang on the guide
strand [63–66]. One of the most reliable design strategies
for generating strand-biased siRNAs is to use asymmetric
25/27-nucleotide DsiRNAs [64, 65]. After processing by
Dicer, the guide strand from the asymmetric 25/27mer
DsiRNA is preferentially incorporated into the RISC, al-
though the siRNA potency can still be influenced by
thermodynamic stabilities at both ends [67, 68].
In addition, overloading can be avoided by limiting the
amounts of exogenous RNA added or by using single
stranded siRNA [69]. Toxicity in vivo often results from the
immunogenic effects of introducing foreign RNA into cells.
Most issues arise as a result of IFN-α production following
Toll-like receptor 7/8 activation. These issues can be abro-
gated by replacing uridines with 2′-O-methyluridine in
siRNAs [70]. Additionally, delivery agents may cause harm-
ful side effects because the introduced RNA is trafficked
through pathways that expose them to the innate immune
system. For example, liposome-mediated delivery of siRNA
exposes the RNA to endosomal Toll-like receptors, cyto-
plasmic RIG-I and protein kinase R (PKR), and other in-
flammatory pathways [71, 72]. Other delivery agents expose
the RNA to a completely different set of pattern recognition
receptors, resulting in an interferon response and inflam-
mation [73].
Therapeutic RNA interference strategies
Many researchers have used RNAi to develop therapeu-
tics against acute and persistent viral infections, andseveral clinical trials have been carried out. For acute
viral infections, siRNA treatments for respiratory syncytial
virus (NCT01065935) and influenza (NCT01747148) are
currently in clinical trials. These viruses present good
targets for RNAi therapeutics because they cause acute
infections with pathogenic effects that can be pre-
vented using this approach. In addition, an acute in-
fection is often localized to a single organ or region,
requiring only a relatively straightforward delivery ap-
proach for RNAi. To date, Alnylam (Cambridge, MA,
USA) has successfully conducted phase II clinical trials
using the RNAi therapeutic ALN-RSV01, which targets
RSV nucleocapsid RNA [74]. Safety and tolerability have
been reported, paving the way for future clinical trials to
investigate efficacy.
RNAi approaches have also been investigated to treat
persistent viral infections such as HIV-1, hepatitis B, and
hepatitis C. These are targeted in a different manner to
acute infections because the RNA therapy must be present
for a longer period of time [75, 76]. The pre-clinical effi-
cacy is promising; nevertheless, a different set of problems
are associated with using RNAi for long-term infections
and these issues must be further explored before moving
to the clinic [77, 78]. The viral proteins and cellular ma-
chinery necessary for viral replication are obvious targets
for preventing initial infection, but viral targets are suscep-
tible to mutational escape resulting from the relatively low
fidelity of the viral RNA polymerase enzymes. Addition-
ally, in the case of HIV-1, cells may be infected with latent
virus that can persist for years before viral production,
with no or only low levels of viral mRNA being produced
during the latent period. Nevertheless, in vitro targeting of
initial HIV-1 infection has been very successful at inhibit-
ing viral replication and the infection of new cells [79, 80].
Translating the success of RNAi against HIV-1 in vitro to
an in vivo or clinical setting has been hampered by prob-
lems with delivery and sustained expression [81, 82]. An
optimal delivery agent would efficiently target only those
cells with the potential to be infected by HIV-1, or
already-infected cells. Current delivery methods do not
offer this advantage, so non-specific or ex vivo methods
are used. Enhancing RNAi expression is also necessary to
advance therapeutics to a clinical setting; this can be
achieved by increasing the molar ratio of RNAi to delivery
reagent or by improving the potency of the RNAi [83]. Al-
ternatively, the HIV-1 promoter can be targeted using
transcriptional gene silencing to prevent reactivation of
viral production [47, 84]. Peripheral blood mononuclear
cells transduced with a lentivirus expressing shRNA
against the U3 region of HIV-1 successfully repopulated
CD4+ T-cell lineages in mice after HIV-1 infection, sug-
gesting that this approach might be a feasible functional
cure [85]. These approaches are very promising, but must
be carefully assessed because increasing the concentration
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and/or the mutation rate [86, 87].
RNA interference approaches for HIV-1 treatment
RNA-silencing approaches have been designed to control
viral replication by blocking key steps within the viral rep-
lication cycle [88]. Several considerations must be made
when choosing targets for HIV-1 treatment with RNAi
(Table 2), including design strategies to target highly con-
served regions within viral RNAs or cellular mRNAs that
are necessary for viral production [89].
Viral targets
The viral genome (Fig. 1a) consists of several highly con-
served regions that have proven to be useful targets as viral
escape via mutagenesis is less likely in these regions than
in other parts of the genome. To identify highly conserved
regions, it is useful to analyze HIV-1 sequences from global
clades and primary isolates that are available online from
the Los Alamos National Laboratory [90].Table 2 Potential RNAi targets for HIV-1 therapy
Function of target gene
HIV-1 gene targets
Gag Proteolytic processing of the HIV-
Pol Transcription
env Receptor binding and fusion
tat Transcription or RNAi modulation
rev Reverse transcription, integration
nef Immune modulation
pol (integrase) Integration
pol (reverse transcriptase) Reverse transcription
Promoter Transcription
Long terminal repeats Genome expression
Cellular targets
CCR5 Receptor binding and fusion
CXCR4 Receptor binding and fusion









SOCS1 Trafficking or immune modulation
TRBP Immune modulation or RNAi path
TNPO3 Nuclear entry of viral pre-integratSelection of targets for RNAi-based therapies against
HIV-1 is a crucial step in obtaining a long-term thera-
peutic effect without the emergence of resistant strains.
Various steps throughout the HIV-1 replication cycle
have been targeted, although it can be particularly bene-
ficial to inhibit the early stages of infection (class I targets),
such as viral entry, reverse transcription, and integration
[2, 91]. Owing to the versatility of RNAi-based therapeu-
tics against any HIV-1 mRNA sequence, it is also possible
to target steps of the HIV-1 replication cycle that are not
targeted by clinical cART agents (Table 2).
As the unspliced HIV-1 genomic RNA transcripts con-
tain the full sequences for all nine viral genes, it is possible
to design anti-HIV-1 siRNAs against any particular con-
served coding region. Owing to alternative splicing pat-
terns, however, it can be advantageous to design siRNAs
against the common sequences that occur on all spliced
and unspliced HIV-1 transcripts, including the early
spliced viral mRNAs that contain tat, rev, and nef reading
frames. These sequences are among the earliest splicedType of study Reference(s)
1 genome Mouse [95, 168]
Mouse [94]




In vitro [91, 175]
In vitro [176]
Mouse [98]
In vitro [76, 93, 173]
Phase 0/phase I/II [149]
In vitro [120, 177]










way In vitro [75, 125]
ion complex Mouse [140, 151]
Bobbin et al. Genome Medicine  (2015) 7:50 Page 9 of 16transcripts of the integrated provirus. Thus, targeting with
siRNA can inhibit production of the associated protein
and downstream proteins necessary for viral maturation,
because the early proteins are required for production
of late transcripts. Target sites present in the HIV-1 sub-
genomic RNAs, including nef and the untranslated LTR
regions, can be targeted in all spliced and unspliced tran-
scripts. Alterations in the RNA folding and structure
of these regions can, however, lead to RNAi-resistance
[92, 93]. Alternatively, the targeting of genes that encode
the structural and enzymatic proteins required for viral
assembly and infection (including gag, pol, vif, and env)
is effective, despite the fact that these genes are not
found in all transcripts [94–97]. While the integrase
and reverse transcriptase proteins are targeted by dif-
ferent classes of antiretroviral drugs, the coding re-
gions of these proteins can also be targeted by RNAi.
Most approaches have relied on using RNAi to target
viral mRNA transcripts in the cytoplasm, but the HIV-1
promoter may also be targeted by transcriptional gene si-
lencing, which induces epigenetic silencing of the inte-
grated provirus [47, 85, 98, 99].
HIV-1 rapidly escapes drug inhibition and RNAi because
of its high rate of mutation, so finding highly conserved re-
gions of the HIV-1 genome to target with RNAi is a com-
mon strategy. Escape from targeting by mutagenesis at
conserved regions may be restricted by a consequent
loss of viral fitness. A major goal of developing anti-HIV-1
RNAi therapy is to target HIV-1 in a manner that prevents
viral escape; such strategies may include targeting multiple
viral sites and endogenous host factors that are required
for HIV-1 infection and replication.
Owing to the low fidelity of HIV-1 reverse transcriptase,
with an estimated error rate of 3 × 10−5 bases per replica-
tion [100, 101], the virus can evolve to escape most mono-
therapies. A variety of mechanisms are responsible for
RNAi escape, including single-point mutations (which may
disrupt the specific recognition of and binding to the
siRNA-binding site), deletion of the target sequence, and
transcriptional upregulation [102]. Single-point mutations
within the target site of a specific siRNA and mutations
that cause structural changes to the mRNA can abate
guide-strand recognition of the target mRNA, thereby
preventing Ago2-mediated silencing [92, 103–105]. In-
direct resistance, such as mutation of non-targeted sites
within the viral promoter, can lead to upregulation of viral
transcription, thereby allowing viral escape by overwhelm-
ing the RNAi-mediated selective pressure [106, 107].
Mutational escape can be avoided by using combination
siRNAs that target multiple sites, which may act synergis-
tically to lower the overall required siRNA concentration,
or by combining siRNAs with other cART drugs [78, 108].
Like cART, such siRNA-based cocktail approaches in-
crease the threshold for mutational escape, and any HIV-1escape variants that do occur may also result in a loss of
viral fitness [109–111].
Cellular targets
Targeting the host cellular co-factors that are required for
HIV-1 infection is an attractive option for RNAi therapies
because endogenous genes are not as prone to mutational
escape as viral genes, which must undergo reverse tran-
scription by an error-prone polymerase [75, 112]. The con-
cept of generating an HIV-resistant immune system has
been supported by a report on the ‘Berlin Patient’ [113],
an individual with HIV-1 infection who required an allo-
geneic bone marrow transplant for acute myeloid leukemia.
The donor hematopoietic progenitor cells (HPCs) were
homozygous for a CCR5 partial gene deletion (CCR5Δ32).
In the absence of the CCR5 co-receptor on the surface of
the HPC-derived CD4+ T cells, macrophages, and mono-
cytes from the donor, the CCR5-tropic HIV-1 virus was
unable to infect new cells. After the transplant, HIV-1
was no longer present at detectable levels, suggesting
that the patient has been functionally cured of HIV/AIDS
[114, 115]. This approach is not feasible for the majority
of HIV/AIDS patients who do not require bone marrow
transplants for pre-existing cancer, but other modes of cel-
lular targeting can be considered. Moreover, a second at-
tempt at an allogeneic transplant of CCR5Δ32 HPCs was
not successful because CXCR4-tropic virus became dom-
inant after the interruption of cART [116]. Therefore, it
may be necessary to target multiple cellular co-factors, in-
cluding endogenous genes that are required for cell entry,
integration, transcription, and maturation of the virus.
Cellular co-factors that are required for infection in-
clude the CD4 receptor as well as the CCR5 and CXCR4
co-receptors. Targeting these receptors can protect the
cell from viral entry and infection, but this strategy has
limitations depending on the receptor targeted [117, 118].
CCR5 is an attractive target because it is required for
CCR5-tropic viral infection and, because it shares func-
tional redundancy with CCR2, it is not required for the
normal development and function of T-lymphocytes [119].
By contrast, CXCR4 and CD4 receptors are less favored
as targets as they are involved in important cellular pro-
cesses. CXCR4 is required for T-cell maturation, so dis-
ruption of CXCR4 must be targeted only in mature T cells
[118]. Targeting of CD4 is also problematic because of its
significant immunological function [120].
Host factors play a role in the integration of the HIV-1
viral genome into cells. Therefore, the HIV-1 replication
cycle may be disrupted by using these host factors as targets
[75, 121]. Co-factors of integrase, including LEDGF/p75,
Importin-7, and Chaperonin, are potential targets [78].
Elongation factors P-TEFb, Tat-SF1, and SPT5 regulate
HIV-1 transcription by interaction with the Tat protein
[87]. Cyclin T1 interacts with P-TEFb and Tat to initiate
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DDX3 is responsible for the export of spliced HIV-1 tran-
scripts, and human SOCS1 is responsible for trafficking
of HIV-1 gag [123]. Additionally, RNAi has been used to
inhibit several autophagy inhibitory factors that are re-
sponsible for HIV-1 replication and prevention of HIV-1
degradation [121]. As HIV-1 is capable of modulating the
immune system through TRBP-TAR-mediated inhibition
of PKR- or SOCS1-dysregulation of immune activation, si-
lencing these genes results in an antiviral response [124].
RNAi silencing of TRBP can also inhibit HIV-1 replication
[75, 125, 126], but this could potentially disrupt the RNAi
pathway because of the role of TRBP in Dicer processing
and RISC assembly [127]. In general, cellular targets must
be considered with caution because these targets affect
cell growth and function, and because they may be im-
portant for cell signaling not observed in vitro. Another
approach is to use a combination of RNAi or other bio-
logical agents against cellular and viral targets using gene
therapy [128]. There are two clinical trials using this ap-
proach [38, 129], which will be discussed in the ex vivo de-
livery section below.
Delivery
One of the largest hurdles in developing effective gene
therapy is delivery. Considerations for the delivery of RNAi
include immunogenicity, cell type uptake, and specificity.
RNAi-based therapeutics can be delivered as RNA mole-
cules (such as siRNAs or shRNAs), as DNA (plasmids or
minicircles), or as therapeutic transgenes in viral vectors
[130]. Delivery reagents can be targeted to specific cell
types or can be non-specific. The advantage of targeted
delivery is that side effects can be reduced, while increas-
ing the efficiency of delivery to target cells. To date, the
RNAi-based agents that have reached clinical testing
for HIV/AIDS have relied on ex vivo delivery of lenti-
viral vectors into specific cell types, such as CD4+ T cells
or CD34+ HPCs, which are then transfused back into the
patient [2]. Alternatively, in vivo delivery approaches may
utilize non-targeted or targeted delivery agents, which in-
clude non-viral carriers such as liposomes, dendrimers,
and aptamers.
Ex vivo delivery
Ex vivo delivery approaches for RNAi-based therapeutics
include viral vectors, nanoparticles, and electroporation
[131]. The most common of these is ex vivo transduction
with virus, including adenovirus, adeno-associated virus
(AAV), and lentivirus. shRNAs can be encoded in viral
vectors to produce stable cell lines and to transduce cells
that are refractory to transfection, such as hematopoietic
stem cells and T cells [132]. In viral vectors derived from
adenovirus, AAV, and lentivirus, shRNA transcripts driven
by polymerase III promoters synthesize a single-strandhairpin loop that can be incorporated into the RNAi path-
way. Lentivirus is integrative, so the RNAi therapy deliv-
ered is incorporated into the cellular genomic DNA, and
although the site of insertion is semi-random, lentiviral
vectors do not share the same tendency for insertional
oncogenesis as gammaretroviral vectors [133]. As lenti-
viral vectors are constructed using a limited HIV-1 gen-
ome, vector production and transduction of the lentiviral
vector may be poor when expressing vector-encoded
shRNAs that target regions that are common to HIV-1
transcripts and lentiviral vector transcripts, such as the LTR
region, or regions that are encoded by helper plasmids,
such as gag, pol, and rev [134, 135]. Different strategies can
be employed to overcome this restriction by increasing
the amount of helper plasmids [135] or by knocking down
Ago2 with a separate shRNA [136]. As a ssDNA virus,
AAV is mostly non-integrative, although limited inte-
gration occurs at a specific locus within cellular genomic
DNA. Several non-viral approaches have been taken, in-
cluding plasmid delivery in liposomes and other nano-
particles, but this results in very inefficient delivery of
transcripts to T cells; transcripts that are delivered in this
way are also non-integrative, limiting the longevity of their
therapeutic value. Other non-specific strategies are non-
integrative but also have reduced efficiency compared to
lentivirus [137].
The first clinical demonstration of the use of RNAi
against HIV-1 was a phase 0 safety and feasibility clinical
trial conducted by the City of Hope Hospital (Duarte, CA,
USA) and Benitec, Inc. (Sydney, Australia). This study
involved transducing human CD34+ HPCs with a self-
inactivating and non-replicating lentivirus containing a tat/
rev shRNA, a TAR decoy, and a CCR5 ribozyme [38]. Four
patients with AIDS-related lymphoma received autologous
bone marrow transplants with lentiviral-transduced CD34+
HPCs in an effort to treat both lymphoma and HIV/AIDS.
The lentiviral-based therapy was well tolerated and no
drug-related adverse events were observed in the four pa-
tients. Expression of the shRNA and ribozyme compo-
nents was detected in the peripheral blood and bone
marrow of all four patients for at least 8 months, and
for more than 3 years in one patient [38, 39]. More re-
cently, we have developed a next-generation lentiviral con-
struct that expresses three small anti-HIV-1 RNAs from
the MCM7 intron and a fourth CCR5 shRNA from the
tRNASer promoter [136, 138].
Calimmune, Inc. (Los Angeles, CA, USA) has developed
a similar strategy using a dual-therapeutic anti-HIV-1 len-
tiviral vector that expresses a CCR5 shRNA and a C46
peptide, which is derived from the HIV-1 gp41 envelope
protein that inhibits viral fusion [139]. In a current phase
I/II trial (NCT01734850), the anti-HIV-1 vector is trans-
duced ex vivo into autologous CD34+ HPCs and CD4+
T-lymphocytes, which are then transplanted back into
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ponent is capable of inhibiting CCR5-tropic (R5-tropic)
but not CXCR4-tropic (X4-tropic) strains, whereas the
C46 peptide inhibits both tropisms of HIV-1 and is thus
an essential factor in the dual-therapeutic design of the
vector.
Non-specific in vivo delivery
A variety of nanoparticles have been used for encapsulat-
ing and delivering HIV-1 siRNAs, including dendrimers,
polymers, and liposomes. Using the G5 PAMAM (gener-
ation 5 polyamidoamine) dendrimer with three anti-HIV-
1 DsiRNAs, HIV-1 replication was potently suppressed in
a humanized mouse model [140]. This cocktail strategy
combined one DsiRNA against the HIV-1 tat/rev overlap-
ping reading frame, another DsiRNA against the host
CD4 receptor, and a third DsiRNA against Transportin-3
(TNPO3), which is a host factor required for nuclear
entry of the HIV-1 pre-integration complex. Biodegrad-
able polymers can protect siRNAs from ribonuclease deg-
radation but release the siRNAs upon cell entry. This
design was used to encapsulate CCR5 siRNAs in a poly-
mer nanocapsule to knockdown levels of CCR5 with sig-
nificantly greater efficiency than liposome-based delivery
systems [141].
Advances in electroporation are creating opportunity
for siRNA delivery in vivo. RNAi has been delivered to
the brain, muscle, and skin [142, 143]. Most recently,
Inovio Pharmaceuticals, Inc. (Blue Bell, PA, USA) has de-
veloped ELGEN in vivo surface electroporation for deliv-
ery of siRNA [142] or DNA vaccines to CD4+ memory T
cells [144, 145], which is promising because memory T
cells are typically thought to be reservoirs for HIV-1. This
strategy has yet to be tested with siRNA against HIV-1 tar-
gets, and in vivo electroporation will need to target a
wider range of locations that include other regions of high
T-cell concentration, such as the spleen and blood.
Targeted delivery
Targeted delivery approaches include the use of tissue-
specific serotypes of AAV, nucleic acid aptamers, anti-
bodies, and modified nanoparticles. These approaches
are non-integrative, but each has its own set of chal-
lenges that need to be considered in order to obtain an
effective delivery method.
AAV is a DNA virus that is used for gene therapy and
that undergoes limited integration into host genomes.
AAV serotypes are selected for specificity to certain re-
gions of an organism. For example, AAV2 targets heparan
sulfate proteoglycan, αVβ5 integrin and fibroblast growth
receptor 1, which is found on hepatocytes, skeletal muscle
cells, smooth muscle cells, and neurons [146]. AAV is a
very effective vector for gene therapy, but the vector has
limited space for exogenous gene insertion and cantypically only be delivered once because of its immuno-
genic properties [147].
Cell-specific nanoparticles comprise another class of
targeted delivery molecules that include aptamers, anti-
bodies, and targeted lipid nanoparticles. These particles
are very small and often must overcome multiple barriers,
such as the cell membrane and endosome, for the siRNA
to be loaded into the RISC. Targeted lipid nanoparticles
are widely used to deliver siRNA in vitro, but can also be
applied in vivo by conjugating a variety of functionalities
to liposomes [71, 148, 149]. These functionalities include
proteins, chemical conjugates, and beads. RNAi molecules
are encapsulated in a lipid bilayer with targeting molecules
facing outwards to bind to receptors of interest.
Aptamers and antibodies selectively deliver siRNAs to
cells of interest by binding to surface receptors and then
entering the cells by receptor-mediated endocytosis. Unlike
some siRNA-nanoparticle designs, aptamers or antibodies
do not bestow a protective layer around the siRNAs, so the
siRNAs are susceptible to nucleases if not modified. Apta-
mers are selected through the systematic evolution of
ligands by exponential enrichment, and are similar to
antibodies in binding affinity and specificity to the target
receptor or protein. Several delivery targets for these
molecules include the HIV-1 gp120 protein and the
CD4 receptor [150–152]. These particles are typically not
immunogenic, but are rapidly cleared from the circulation
and are non-integrative, so multiple doses of anti-HIV-1
siRNAs must be given [149, 153]. Dimeric bacteriophage
pRNA complexes have been engineered with an HIV-1
gp120 aptamer and a tat/rev siRNA for targeted delivery
to HIV-infected cells [154]. Antibodies have also been
used to deliver siRNAs in cell-specific fashion, including
gag siRNAs complexed with a protamine-gp160 antibody
fusion protein [155] and siRNAs against the CCR5 co-
receptor and viral genes tat and vif conjugated with poly-
(D)-arginine and a CD7 antibody [156].
Microbicides loaded with siRNAs or aptamer-siRNAs
are designed to prevent the transmission of the virus, and
their efficacy is increased by targeting localized areas. CD4
aptamer-siRNA chimeras can be administered topically as
microbicides for prophylaxis against HIV-1 [150, 157]. In
other systems, the siRNA is either naked or conjugated to
cholesterol and applied topically to the skin, and results in
prevention of viral transmission [158]. For complete and
effective HIV-1 prophylaxis, however, siRNA microbicides
must achieve durable protection from HIV-1, broad target
specificity against potential viral variants, and favorable
kinetics for cellular uptake and virus neutralization.
Conclusions
The potential for RNAi to be used against HIV-1 in the
clinic is feasible with improvements in current strategies.
Several points to consider when using RNAi to treat
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mutagenesis. In this review, we have discussed strategies
that are used to overcome problems in each of these areas.
Modified base incorporation and improved siRNA specifi-
city have led the way in reducing the immunogenicity and
improving efficacy. In addition, target identification has
produced a wide array of viral and cellular targets that in-
hibit HIV-1 replication upon silencing. As a therapeutic,
siRNAs have great promise due to their target specificity,
potency, and ability to be chemically synthesized for
manufacturing. They are widely adaptable, which is advan-
tageous in the case of HIV-1 mutagenesis. By developing a
platform for clinical use of RNAi against HIV, targets can
be changed rapidly as the virus mutates.
The mode of delivery remains one of the highest hurdles
in bringing RNAi to the clinic to treat HIV. To have an ef-
fective siRNA therapeutic, delivery must efficiently reach
the intended cells and tissues. To date, the most efficient
delivery methods are viral vectors, including the ex vivo
transduction of cells with lentivirus and in vivo delivery
with AAV. Unfortunately, these delivery types are only
moderately specific, and AAV is prone to inducing an
immunogenic response in vivo. More targeted delivery
methods are applicable in an in vivo setting, where they
offer specificity and reduced immunogenicity; neverthe-
less, these methods often lack the pharmacokinetics and
scalability of non-specific delivery carriers. Therefore, con-
tinued progress to improve each of these shortcomings
is required to fulfill the promise of RNAi therapeutics
for HIV.
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